Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2026 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD...
January 06, 2026 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...
December 22, 2025 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside...